Catalent Signs Agreement to Acquire Juniper Pharmaceuticals, Inc.

Catalent Signs Agreement to Acquire Juniper Pharmaceuticals, Inc. $133 Million Deal Adds European Early Development Center of Excellence to Global Network   SOMERSET, N.J., July 3, 2018 – Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has […]

Read More

Catalent Biologics Adopts Berkeley Lights’ Beacon® Optofluidic Platform to Accelerate Cell Line Development

Catalent Biologics Adopts Berkeley Lights’ Beacon® Optofluidic Platform to Accelerate Cell Line Development   SOMERSET, N.J. – July 10, 2018 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Berkeley Lights, Inc. (BLI), a leader in digital cell biology, today announced […]

Read More

China’s CROs Make Connection in S.D. #BiocomCRO

PHARMA: THEY’RE PART OF GROWING BIOTECH RELATIONSHIP China’s CROs Make Connection in S.D. By Jared Whitlock Sunday, June 10, 2018   San Diego — In San Diego, the last decade gave rise to biotechs farming out work to contract research organizations, or CROs. It’s an industry increasingly colored by China. In recent years, Chinese-linked CROs, led by […]

Read More

Catalent Biologics Supports InterveXion on New Treatment for Methamphetamine Users

SOMERSET, N.J. – May 31, 2018 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today welcomed the news that InterveXion has enrolled the first patient in STAMPOUT, the first trial in methamphetamine users of the first-in-class anti-methamphetamine antibody IXT-m200. STAMPOUT will […]

Read More

Rapid Novor is developing a non-invasive, blood-based test for the multiple myeloma patients’ Minimal Residual Disease (MRD) assessment and monitoring

Have you just developed a new technology that potential partners need to discover? Share it with us and describe how it can be used to further research, drug development, and/or innovation. Our company Rapid Novor is developing a non-invasive, blood-based test for the multiple myeloma patients’ Minimal Residual Disease (MRD) assessment and monitoring. We use the mass […]

Read More

GLP Accreditation Renewal for Wax-it Histology Services Inc.

GLP Accreditation Renewal for Wax-it Histology Services Inc. VANCOUVER, BC (May 8, 2018) – Wax-it Histology Services Inc. is pleased to announce that the Standard Council of Canada’s (SCC) annual inspection of the company’s facility, SOPs and completed studies has come to a close and GLP (Good Laboratory Practice) Accreditation for the facility has been renewed. The […]

Read More

Wax-it Histology Services Inc. brings in new state-of-the-art equipment for IHC staining: Ventana BenchMark XT

VANCOUVER, BC (May 2, 2018) — Wax-it Histology Services Inc. is excited to announce the implementation of the Ventana BenchMark XT automated IHC staining system to their laboratory. This state-of-the-art machine gives the company the capability to produce high-quality and reproducible IHC stained slides with unparalleled efficiency. The entire IHC team has been fully trained to […]

Read More